Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Survivorship and complications of treatment in breast cancer.

Identifieur interne : 007E66 ( Main/Exploration ); précédent : 007E65; suivant : 007E67

Survivorship and complications of treatment in breast cancer.

Auteurs : Ewa Mrozek [États-Unis] ; Charles L. Shapiro

Source :

RBID : pubmed:16166992

Descripteurs français

English descriptors

Abstract

The majority of women treated today for breast cancer are long-term survivors. The overall benefits of adjuvant therapy in women with breast cancer favor treatment even in the subset of patients with node-negative invasive breast cancer. The short- and long-term side effects of combined modality treatment have a significant impact on morbidity and quality of life. Continued emphasis on improving survival, decreasing recurrence, and minimizing treatment toxicity are the goals of ongoing breast cancer research.

PubMed: 16166992


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Survivorship and complications of treatment in breast cancer.</title>
<author>
<name sortKey="Mrozek, Ewa" sort="Mrozek, Ewa" uniqKey="Mrozek E" first="Ewa" last="Mrozek">Ewa Mrozek</name>
<affiliation wicri:level="2">
<nlm:affiliation>Division of Hematology/Oncology and Comprehensive Breast Health Services, Ohio State University Medical Center, Columbus, OH 43210, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology/Oncology and Comprehensive Breast Health Services, Ohio State University Medical Center, Columbus, OH 43210</wicri:regionArea>
<placeName>
<region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Shapiro, Charles L" sort="Shapiro, Charles L" uniqKey="Shapiro C" first="Charles L" last="Shapiro">Charles L. Shapiro</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:16166992</idno>
<idno type="pmid">16166992</idno>
<idno type="wicri:Area/PubMed/Corpus">003C01</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003C01</idno>
<idno type="wicri:Area/PubMed/Curation">003C01</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003C01</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003C01</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003C01</idno>
<idno type="wicri:Area/Ncbi/Merge">001F58</idno>
<idno type="wicri:Area/Ncbi/Curation">001F58</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001F58</idno>
<idno type="wicri:doubleKey">1543-0790:2005:Mrozek E:survivorship:and:complications</idno>
<idno type="wicri:Area/Main/Merge">008070</idno>
<idno type="wicri:Area/Main/Curation">007E66</idno>
<idno type="wicri:Area/Main/Exploration">007E66</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Survivorship and complications of treatment in breast cancer.</title>
<author>
<name sortKey="Mrozek, Ewa" sort="Mrozek, Ewa" uniqKey="Mrozek E" first="Ewa" last="Mrozek">Ewa Mrozek</name>
<affiliation wicri:level="2">
<nlm:affiliation>Division of Hematology/Oncology and Comprehensive Breast Health Services, Ohio State University Medical Center, Columbus, OH 43210, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Hematology/Oncology and Comprehensive Breast Health Services, Ohio State University Medical Center, Columbus, OH 43210</wicri:regionArea>
<placeName>
<region type="state">Ohio</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Shapiro, Charles L" sort="Shapiro, Charles L" uniqKey="Shapiro C" first="Charles L" last="Shapiro">Charles L. Shapiro</name>
</author>
</analytic>
<series>
<title level="j">Clinical advances in hematology & oncology : H&O</title>
<idno type="ISSN">1543-0790</idno>
<imprint>
<date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adrenal Cortex Hormones (therapeutic use)</term>
<term>Adult</term>
<term>Antineoplastic Agents, Hormonal (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term>
<term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term>
<term>Brachial Plexus Neuropathies (etiology)</term>
<term>Breast Neoplasms (drug therapy)</term>
<term>Breast Neoplasms (mortality)</term>
<term>Breast Neoplasms (radiotherapy)</term>
<term>Breast Neoplasms (surgery)</term>
<term>Breast Neoplasms (therapy)</term>
<term>Cardiovascular Diseases (etiology)</term>
<term>Chemotherapy, Adjuvant (adverse effects)</term>
<term>Cognition Disorders (chemically induced)</term>
<term>Endometrial Neoplasms (chemically induced)</term>
<term>Fatigue (chemically induced)</term>
<term>Female</term>
<term>Humans</term>
<term>Lymphedema (etiology)</term>
<term>Lymphedema (therapy)</term>
<term>Mastectomy</term>
<term>Neoplasms, Radiation-Induced (epidemiology)</term>
<term>Neoplasms, Radiation-Induced (etiology)</term>
<term>Neoplasms, Second Primary (epidemiology)</term>
<term>Neoplasms, Second Primary (etiology)</term>
<term>Osteoporosis (chemically induced)</term>
<term>Postoperative Complications (etiology)</term>
<term>Pregnancy</term>
<term>Primary Ovarian Insufficiency (chemically induced)</term>
<term>Radiation Injuries (etiology)</term>
<term>Radiation Pneumonitis (drug therapy)</term>
<term>Radiation Pneumonitis (etiology)</term>
<term>Radiotherapy (adverse effects)</term>
<term>Radiotherapy (methods)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Survivors</term>
<term>Thrombosis (chemically induced)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte</term>
<term>Antinéoplasiques hormonaux (effets indésirables)</term>
<term>Complications postopératoires (étiologie)</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Fatigue ()</term>
<term>Femelle</term>
<term>Grossesse</term>
<term>Hormones corticosurrénaliennes (usage thérapeutique)</term>
<term>Humains</term>
<term>Insuffisance ovarienne primitive ()</term>
<term>Lymphoedème ()</term>
<term>Lymphoedème (étiologie)</term>
<term>Lésions radio-induites (étiologie)</term>
<term>Maladies cardiovasculaires (étiologie)</term>
<term>Mastectomie</term>
<term>Neuropathies du plexus brachial (étiologie)</term>
<term>Ostéoporose ()</term>
<term>Pneumopathie radique (traitement médicamenteux)</term>
<term>Pneumopathie radique (étiologie)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term>
<term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term>
<term>Radiothérapie ()</term>
<term>Radiothérapie (effets indésirables)</term>
<term>Seconde tumeur primitive (épidémiologie)</term>
<term>Seconde tumeur primitive (étiologie)</term>
<term>Survivants</term>
<term>Thrombose ()</term>
<term>Traitement médicamenteux adjuvant (effets indésirables)</term>
<term>Troubles de la cognition ()</term>
<term>Tumeurs de l'endomètre ()</term>
<term>Tumeurs du sein ()</term>
<term>Tumeurs du sein (mortalité)</term>
<term>Tumeurs du sein (radiothérapie)</term>
<term>Tumeurs du sein (traitement médicamenteux)</term>
<term>Tumeurs radio-induites (épidémiologie)</term>
<term>Tumeurs radio-induites (étiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antineoplastic Agents, Hormonal</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Adrenal Cortex Hormones</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
<term>Chemotherapy, Adjuvant</term>
<term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en">
<term>Cognition Disorders</term>
<term>Endometrial Neoplasms</term>
<term>Fatigue</term>
<term>Osteoporosis</term>
<term>Primary Ovarian Insufficiency</term>
<term>Thrombosis</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Breast Neoplasms</term>
<term>Radiation Pneumonitis</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Antinéoplasiques hormonaux</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
<term>Radiothérapie</term>
<term>Traitement médicamenteux adjuvant</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Neoplasms, Radiation-Induced</term>
<term>Neoplasms, Second Primary</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Brachial Plexus Neuropathies</term>
<term>Cardiovascular Diseases</term>
<term>Lymphedema</term>
<term>Neoplasms, Radiation-Induced</term>
<term>Neoplasms, Second Primary</term>
<term>Postoperative Complications</term>
<term>Radiation Injuries</term>
<term>Radiation Pneumonitis</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Radiotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr">
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr">
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en">
<term>Antineoplastic Combined Chemotherapy Protocols</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Breast Neoplasms</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Pneumopathie radique</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Hormones corticosurrénaliennes</term>
<term>Protocoles de polychimiothérapie antinéoplasique</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Seconde tumeur primitive</term>
<term>Tumeurs radio-induites</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Complications postopératoires</term>
<term>Lymphoedème</term>
<term>Lésions radio-induites</term>
<term>Maladies cardiovasculaires</term>
<term>Neuropathies du plexus brachial</term>
<term>Pneumopathie radique</term>
<term>Seconde tumeur primitive</term>
<term>Tumeurs radio-induites</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Female</term>
<term>Humans</term>
<term>Mastectomy</term>
<term>Pregnancy</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Survivors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Fatigue</term>
<term>Femelle</term>
<term>Grossesse</term>
<term>Humains</term>
<term>Insuffisance ovarienne primitive</term>
<term>Lymphoedème</term>
<term>Mastectomie</term>
<term>Ostéoporose</term>
<term>Radiothérapie</term>
<term>Survivants</term>
<term>Thrombose</term>
<term>Troubles de la cognition</term>
<term>Tumeurs de l'endomètre</term>
<term>Tumeurs du sein</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The majority of women treated today for breast cancer are long-term survivors. The overall benefits of adjuvant therapy in women with breast cancer favor treatment even in the subset of patients with node-negative invasive breast cancer. The short- and long-term side effects of combined modality treatment have a significant impact on morbidity and quality of life. Continued emphasis on improving survival, decreasing recurrence, and minimizing treatment toxicity are the goals of ongoing breast cancer research.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Ohio</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Shapiro, Charles L" sort="Shapiro, Charles L" uniqKey="Shapiro C" first="Charles L" last="Shapiro">Charles L. Shapiro</name>
</noCountry>
<country name="États-Unis">
<region name="Ohio">
<name sortKey="Mrozek, Ewa" sort="Mrozek, Ewa" uniqKey="Mrozek E" first="Ewa" last="Mrozek">Ewa Mrozek</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007E66 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007E66 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:16166992
   |texte=   Survivorship and complications of treatment in breast cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:16166992" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024